AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06380127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
Study NCT04736615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAFEWATER systems for drinking water disinfection
Description: A domestic water purification technology, consisting of a raw water storage tank, a pump, a filtration unit (2 cartridge filters), a UVC disinfection unit (UV lamp), a storage tank for drinking water (treated and safe water), and a distribution network inside the house for drinking water.
Study NCT04736615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change interventions
Description: Targeting behaviors around the use of the technology and water more generally. Behavioral interventions will be data-driven (i.e., dependent on the problems that arise) but are likely to include household and community-level activities.
Study NCT06301620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.
Study NCT05494073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction with Hybrid Remnant Repair
Description: The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
Study NCT05494073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction without Hybrid Remnant Repair
Description: ACL reconstruction without preservation or incorporation of host ACL remnant
Study NCT04851678 — intervention group
Intervention type: OTHER
Intervention: None - observational study
Description: None - observational study
Study NCT06301620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation treatment
Description: Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance.
Study NCT06301620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intra-articular Injection
Description: The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
Study NCT06457893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The health belief model-based exercise training program and health belief model-based education
Description: The health belief model-based exercise training program and education program will implement with the students in the experimental group for 5 weeks and follow-ups will be made at the 3rd and 6th months.
Study NCT06334224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low load resistance training with blood flow restriction
Description: The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
Study NCT06334224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low load resistance training
Description: Leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
Study NCT05141461 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Group C
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalen area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 100 ml of NACI will be given intravenously within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively.
Study NCT05141461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group Dex
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, a 50 mm block needle will be advanced into the interscalene area using the in-plane method. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area. 5 mg dexamethasone intravenously will be given in 100 ml NACI within 15 minutes.~General anesthesia will be performed using 2 mg/kg of propofol and 1-2 µg/kg of fentanyl. Tracheal intubation will be facilitated with 0.6mg/kg rocuronium. Anesthesia will be maintained using 50% oxygen and 2% sevoflurane. Patients will be extubated into the operating room after reversing residual muscle relaxation. A multimodal analgesia regimen will be applied postoperatively.
Study NCT05031533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Painting Radiation
Description: Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy
Study NCT06166329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chair lift test
Description: repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
Study NCT06370065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）
Description: PD-1 inhibitor
Study NCT05156606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AndroGel
Description: After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
Study NCT06210152 — intervention group
Intervention type: DEVICE
Intervention: Radial Extracorporeal Shockwave Therapy
Description: Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.
Study NCT06210152 — intervention group
Intervention type: DEVICE
Intervention: Sham Extracorporeal Shockwave Therapy
Description: Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
Study NCT05148052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality exergames
Description: Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
Study NCT05148052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy
Description: Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
Study NCT06240351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib is a Janus kinase (JAK) inhibitor
Study NCT04863365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: A matching placebo ophthalmic solution, 3 drops daily, 28 days
Study NCT04863365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHP-201 ophthalmic solution
Description: PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
Study NCT05588011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo
Description: A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
Study NCT05588011 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LivaNova
Description: A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
Study NCT02476474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 cm start of resection
Description: Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
Study NCT02476474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cm start of resection
Description: Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
Study NCT05632276 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ConvaFoam
Description: ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
Study NCT06544031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Nutrition Education Program
Description: The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
Study NCT04788862 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum infected erythrocytes
Description: Chloroquine sensitive P. falciparum 3D7-infected red blood cells, thawed and prepared under strict aseptic conditions, will be used as a challenge agent.
Study NCT04046172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supra/sub gingival root surface debridement
Description: The test group will undergo Intensive periodontal treatment (IPT)
Study NCT04046172 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: supra-gingival scaling and polishing
Description: Control group will receive the Control periodontal treatment (CPT).
Study NCT05218226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count >100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
Study NCT06316973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1103
Description: CS-1103 for infusion
Study NCT06316973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Sterile Saline for Injection
Study NCT05266560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: A new type of anesthetic drug, Ciprofol, which is newly listed and has national independent intellectual property rights, is an analogue of propofol. Its chemical name is 2-\[(1R)-1-cyclopropylethyl\]-6-isopropyl-phenol, and it acts on GABAA receptors like propofol. Compared with propofol, ciprofol is 4-5 times more potent, which can significantly reduce the amount of anesthetics.
Study NCT05266560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is a commonly used anesthetic in clinical practice and is often used before ECT.
Study NCT06182696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OriCAR-017
Description: GPCRC5D-directed chimeric antigen receptor modified T cells
Study NCT05788133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment and screening by neuropsychological tests on humanoid robot
Description: treatment and screening by neuropsychological tests on humanoid robot
Study NCT04887012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK
Description: lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR
Study NCT06504069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial VR intervention
Description: A five-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include five weekly sessions, each lasting between 10 to 15 minutes. Each session will depict a different daily life scenario-home, school, street, park, and shopping mall, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
Study NCT04777162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: For included participants, tislelizumab would be administrated 200mg q3w iv.
Study NCT04777162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
Study NCT04675268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oximetry
Description: A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
Study NCT05603403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiatop
Description: 1 sachet orally, 2 times a day, for 42 days
Study NCT05603403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet orally, 2 times a day, for 42 days
Study NCT05118802 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Attends Interviews
Study NCT05118802 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete Survey
Study NCT05718037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: 0.5mL, Intramuscular
Study NCT05718037 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL, Intramuscular
Study NCT05718037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zoster Vaccine Recombinant, Adjuvanted
Description: 0.5mL, Intramuscular
Study NCT05696574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol
Description: Women in this group will include 40 pregnant women who will be offered misoprostol (placed in the post-fornix of the vagina) in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
Study NCT05696574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Description: Women in this group will include 40 pregnant women who will be offered oral misoprostol in a dose of 25µg to be repeated every 6 hours if no response is achieved with a maximum of 4 doses.
Study NCT06187168 — intervention group
Intervention type: PROCEDURE
Intervention: exposure to hypotension during the Endoscopic Retrograde Cholangiopancreatography (ERCP) for obstructive jundice.
Description: This is not an intended intervention in the study. This cohort study will study the exposure to intraoperative hypotension and the occurrence of sepsis after the ERCP procedures.
Study NCT05235919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 30 minutes rTMS session 5 days/week for 3 weeks.
Study NCT05235919 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 30 minutes sham stimulation 5 days/week for 3 weeks.
Study NCT06362863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition biscuits
Description: Addition of enteral nutritional biscuits to existing pharmacological treatment.
Study NCT05567770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinium-J591
Description: Cohort 1 with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Study NCT06516744 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bye Bye Bloat Capsules
Description: Bye Bye Bloat Capsules contain the following ingredients: Organic Fenugreek Seed Powder, Organic Dandelion Root Powder, Organic Fennel Seed Powder, Organic Ginger Root Powder, Organic Parsley Leaf Powder, Amylase Complex, Protease Complex, Pepsin Complex, Lipase Complex, Bromelain Complex, Papain Complex. Other ingredients include Hypromellose Capsule, Maltodextrin, Microcrystalline Cellulose, and Magnesium Stearate. Participants will take 2 capsules immediately after eating at least 3 times a week and during times of hormonal bloating for 4 weeks.
Study NCT05843318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water intake and weight control in older adults - Premeal Water + hypocaloric diet
Description: Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
Study NCT05843318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water intake and weight control in older adults - Total Daily Water + hypocaloric diet
Description: Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.